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Summary 
Alzheimer’s disease (AD) is the most common cause of dementia and presents a growing 
challenge to global health. AD is pathologically characterised by extracellular amyloid plaques 
(Aβ) and intraneuronal neurofibrillary tangles. Another key pathological feature of AD is 
chronic neuroinflammation suggesting that microglia, the major immune cell type in the brain, 
play an important role in AD progression. These pathological features have been known for 
over 115 years, yet the underlying mechanisms that connect these pathologies and result in AD 
are still unknown. Extensive evidence from recent genome wide association studies suggest 
that the innate immunomodulatory receptor, the triggering receptor expressed on myeloid cells-
2 (TREM21), plays a crucial role in sustaining the microglial response to disease pathogenesis. 
TREM2 is second only to apolipoprotein E (APOE2), the strongest genetic risk factor of AD, 
in terms of the magnitude of its effects as a late-onset AD risk factor.  
Studies using AD mouse models show that Trem2 is selectively expressed in microglia that 
cluster around Aβ plaques and is required for a variety of important microglial functions related 
to phagocytosis of cellular debris and Aβ fibrils. Although loss of Trem2 expression in AD 
mouse models was reported to decrease Aβ-associated microglia, contradictory effects on Aβ 
pathology were published. Therefore, to study the effects of TREM2 on premature Aβ plaque 
formation and deposition, I experimentally induced cerebral amyloidosis by stereotaxically 
injecting brain extract from aged Aβ plaque-bearing APPPS1 mice into the hippocampi of 
APPPS1/Trem2+/+, APPPS1/Trem2-/-, and APPPS1/Trem2p.T66M mice, at an age when no 
plaques had yet formed. I used APPPS1/Trem2p.T66M mice as an additional loss of Trem2 
function control as I, together with Gernot Kleinberger, published that the frontotemporal 
dementia-like disorder-associated p.T66M mutation reduces soluble Trem2 levels in vivo as a 
result of impaired Trem2 maturation and shedding (Kleinberger et al., 2017). Using this 
experimental paradigm, I found that Aβ seeding was significantly increased in the loss of 
Trem2 function APPPS1 mice compared to controls. I also confirmed that Trem2-deficiency 
impaired the capacity of microglia to remove Aβ seeds, most likely due to reduced IBA1- and 
CD68-positive microglia around plaques. Similar increase in plaque deposition and reduction 
in microglial activity was observed in Trem2-deficient APPPS1 mice during aging using 
longitudinal positron emission tomography. Surprisingly, while the rate of amyloidogenesis in 
Trem2-deficient APPPS1 mice consistently contradicted APPPS1/Trem2+/+ controls 
throughout aging, the plaque deposition in both models levelled out at 12 months. These data 
indicate that additional factors may influence Aβ accumulation, including its aggregation and 
clearance during aging. Moreover, the seeded plaque morphology in loss of Trem2 function 
APPPS1 mice appeared diffuse with less compact cores despite the increase in total Aβ burden. 
This was contradictory to what I expected considering that the reduction in microglial clearance 
of Aβ plaques may instead result in increased cored aggregates due to decreased phagocytosis 
of the plaque halo. 
                                                          
1 TREM2 – Human ortholog for gene and protein. Italicized for gene. Also used to describe the protein 
generally. Trem2 – Mouse ortholog for both gene and protein. 
2 APOE – Human and mouse ortholog. Italicized for gene. Also used to describe the protein generally. 
 ApoE – human and mouse ortholog to describe the protein. 
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Two recent studies independently reported that TREM2 binds to APOE and APOE mRNA 
expression is upregulated in plaque-surrounding microglia similarly to TREM2, suggesting 
that the TREM2-APOE interaction may regulate the microglial phenotypic changes in AD. As 
APOE is known to strongly localise with Aβ dense core plaques in AD as well as affect Aβ 
aggregation and clearance, I hypothesized that plaque-associated microglia may be critical to 
mitigating amyloid metabolism by inadvertently promoting Aβ aggregation in attempt to clear 
Aβ instead. To address this hypothesis, I performed three different sets of experiments. Firstly, 
I performed immunohistochemical analyses on exogenously seeded, that is, Aβ brain extract 
injected, as well as aged APPPS1 mice, with and without functional Trem2. By performing 
costainings for ApoE, Aβ, IBA1-expressing microglia and GFAP-expressing astrocytes, I 
observed a dramatic decrease in plaque-associated ApoE levels upon loss of Trem2 function 
in both seeded and aged mice. I found that compared to loss of Trem2 function mice, the IBA1-
positive microglia around plaques in APPPS1/Trem2+/+ showed a strong colocalisation with 
ApoE, whereas no Trem2-dependent changes in ApoE/GFAP colocalisation was detected. This 
was unexpected considering ApoE is reported as mainly being produced by astrocytes and only 
to a lesser extent in microglia. Secondly, in a collaborative effort, we analysed microglia-
enriched and microglia-depleted fractions in APPPS1 mice, the latter fraction containing 
mostly astrocytes as well as oligodendrocytes and neurons to a lesser extent, to compare 
relative ApoE protein induction in these fractions using mass spectrometry. Indeed, the 
microglia-enriched fraction produced more ApoE in APPPS1/Trem2+/+ compared to 
APPPS1/Trem2-/- mice. Microglia-depleted fractions in these mice did not show any Trem2-
dependent effects, suggesting that while ApoE may mainly be synthesized by astrocytes under 
healthy physiological conditions, microglia may contribute to the overall ApoE production in 
the brain during inflammation. Thirdly, to confirm these findings, I compared plaque-
associated ApoE levels and its glial origin in microglia-depleted APPPS1 mice to age-matched 
controls. ApoE was significantly reduced upon microglia-depletion, indicating that the ApoE 
content in plaques may largely derive from disease-associated microglia. Lastly, to test whether 
these preclinical findings could be translated to humans, I investigated microglia clustering 
around Aβ plaques and its ApoE content in AD patients with different TREM2 coding variants. 
AD patients with TREM2 variants presented impaired microglial association to plaques as well 
as reduced ApoE levels compared to AD cases with the common TREM2 variant, regardless of 
their APOE genotype.  
Taken together, my studies provide the first evidence that loss of Trem2 function not only 
increases early plaque formation due to impaired microglial phagocytosis, but also alters 
the kinetics of amyloidogenesis during aging. In addition, I found that ApoE protein levels 
are strongly induced in plaque-associated microglia under disease conditions in a Trem2-
dependent manner. While the ApoE contribution of astrocytes cannot be completely 
excluded, microglia-depletion in mice and loss-of-function TREM2 coding variants in AD 
patients drastically reduce ApoE in plaques, which in turn may affect Aβ metabolism. 
These results suggest that the TREM2-APOE interaction may initially serve as protective 
means to modulate Aβ plaque clearance but in parallel may exacerbate Aβ pathology. 
Therefore, any therapeutic strategy attempting to target microglial function to modulate 
Aβ pathogenesis must consider the effects of TREM2 on APOE. 
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Zusammenfassung 
Die Alzheimer-Krankheit (AD) ist die häufigste Ursache für Demenz und stellt eine wachsende 
Herausforderung für die globale Gesundheit dar. AD ist pathologisch durch extrazelluläre 
Amyloid-Plaques (Aβ) und intraneuronale neurofibrilläre Bündel gekennzeichnet. Ein weiteres 
pathologisches Merkmal von AD ist die chronische Neuroinflammation, was darauf hindeutet, 
dass Mikroglia, der wichtigste Typ von Immunzellen im Gehirn, eine bedeutende Rolle bei der 
AD-Progression spielen. Obwohl diese pathologischen Merkmale seit über 115 Jahren bekannt 
sind, sind die zugrunde liegenden Mechanismen, die zu diesen Pathologien und zu AD führen, 
weiterhin unbekannt. Umfangreiche Beweise aus kürzlich durchgeführten genomweiten 
Assoziationsstudien legen nahe, dass der angeborene immunomodulatorische Rezeptor, der auf 
myeloischen Zellen-2 (TREM2) exprimiert wird, eine entscheidende Rolle bei der 
Aufrechterhaltung der Mikroglia-Reaktion und der  Pathogenese der Erkrankung spielt. 
Darüber hinaus steht TREM2an zweiter Stelle hinter Apolipoprotein E (APOE), dem stärksten 
genetischen Risikofaktor von AD, was die Stärke seiner Auswirkungen als spät einsetzender 
AD-Risikofaktor angeht. 
Studien mit AD-Mausmodellen zeigen, dass Trem2 selektiv in Mikroglia exprimiert wird, die 
sich um Aβ-Plaques herum ansammeln, und für eine Vielzahl wichtiger Mikrogliafunktionen 
benötigt wird, die mit der Phagozytose von Zelltrümmern und Aβ-Fibrillen zusammenhängen. 
Obwohl berichtet wurde, dass der Verlust der Trem2-Expression in AD-Mausmodellen die Aβ-
assoziierten Mikroglia verringert, wurden widersprüchliche Auswirkungen auf die Aβ-
Pathologie veröffentlicht. Um die Auswirkungen von TREM2 auf die Bildung und Ablagerung 
von neu entstandenen Aβ-Plaques zu untersuchen, induzierte ich daher experimentell die 
cerebrale Amyloidose durch stereotaktisches Injizieren von Hirnhomogenat aus gealterten 
APPPS1-Mäusen in die Hippocampi von APPPS1/Trem2+/+ sowie, APPPS1/Trem2-/- und 
APPPS1/Trem2p.T66M Mäusen in einem Alter, in dem sich noch keine Plaques gebildet haben. 
Ich verwendete APPPS1/Trem2p.T66M Mäuse als zusätzliche Kontrolle zum Verlust der Trem2-
Funktion, da ich zusammen mit Gernot Kleinberger veröffentlichte, die mit der 
frontotemporalen Demenz-ähnlichen Störung assoziierte p.T66M-Mutation in vivo lösliche 
Trem2-Spiegel reduziert, als Folge einer beeinträchtigten Trem2-Reifung und -Spaltung 
(Kleinberger et al. 2017). Darüber hinaus fand ich heraus, dass ‚Aβ-Seeding‘ in den 
APPPS1/Trem2-/- und APPPS1/Trem2p.T66M-Mäusen im Vergleich zu den APPPS1/Trem2+/+ 
Kontrollen signifikant erhöht war. Mit diesem Modell bestätigte ich auch, dass der Trem2-
Mangel die Fähigkeit von Mikroglia zur Entfernung von ‚Aβ-Seeds‘ beeinträchtigt, 
höchstwahrscheinlich durch reduzierte IBA1- und CD68-positive Mikroglia um Plaques. Ein 
ähnlicher Anstieg der Plaqueablagerung und der Verringerung der Mikroglia-Aktivität wurde 
während des Alterns bei Trem2-defizienten APPPS1-Mäusen unter Verwendung der 
longitudinalen Positronenemissionstomographie beobachtet. Während die Geschwindigkeit 
der Amyloidogenese bei Trem2-defizienten APPPS1-Mäusen während der gesamten 
Alterungsdauer entgegengesetzt zu den APPPS1/Trem2+/+ Kontrollen verlief, stagnierte die 
Plaqueablagerung bei beiden Mausmodellen überraschenderweise nach 12 Monaten.  Diese 
Daten weisen darauf hin, dass zusätzliche Faktoren die Aβ-Akkumulation und -Beseitigung 
beeinflussen können, und zwar der Stoffwechsel während des Alterns. Darüber hinaus schien 
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die induzierte Plaque-Morphologie beim APPPS1/Trem2-/- und APPPS1/Trem2p.T66M Mäuse 
trotz der Zunahme der gesamten Aβ-Belastung diffus mit weniger kompakten Kernen zu sein. 
Dies stand im Gegensatz zu dem was ich erwartete, da eine Verminderung des Abbaus von 
Aβ-Plaques durch Mikroglia ebenso zu vermehrten Kernaggregaten aufgrund einer erhöhten 
Aβ-Verfügbarkeit sowie einer verringerten Phagozytose des Plaque-Halos führen kann. 
Kürzlich berichteten zwei unabhängige Studien, dass TREM2 an APOE bindet und die APOE-
mRNA-Expression in Plaque-umgebender Mikroglia, ähnlich wie TREM2 hochreguliert, wird, 
was darauf hindeutet, dass die TREM2-APOE-Wechselwirkung die mikroglialen 
phänotypischen Veränderungen in AD regulieren könnte. Da bekannt ist, dass APOE mit 
dichten Aβ-Core-Plaques in AD stark lokalisiert ist und die Aβ-Aggregation und -Beseitigung 
beeinflusst, stellte ich die Hypothese auf, dass Plaque-assoziierte Mikroglia kritisch sein 
können, um den Amyloid-Metabolismus zu mildern, indem bei dem Versuch  Aβ  zu 
beseitigen, stattdessen versehentlich die Aβ-Aggregation begünstigt wird. Um dieser 
Hypothese nachzugehen, führte ich drei verschiedene Experimente durch. Zunächst führte ich 
immunhistochemische Analysen an exogen induzierten und gealterten APPPS1-Mäusen, mit 
und ohne funktionellem Trem2, durch. Durch die Durchführung von Parallelfärbungen für 
ApoE, Aβ, IBA1-exprimierende Mikroglia und GFAP-exprimierende Astrozyten, konnte ich 
eine dramatische Abnahme der Plaque-assoziierten ApoE-Spiegel nach Verlust der Trem2-
Funktion sowohl in injizierten als auch in gealterten Mäusen feststellen. Außerdem stellte ich 
fest, dass die IBA1-positiven Mikroglia um Plaques in APPPS1 im Vergleich zu 
APPPS1/Trem2-/- und APPPS1/Trem2p.T66M-Mäusen eine starke Kolokalisation mit ApoE 
zeigten, während keine Trem2-abhängige Veränderung der ApoE/GFAP-Kolokalisation 
festgestellt wurde. Dies war unerwartet, da zuvor berichtet wurde, dass ApoE hauptsächlich 
von Astrozyten produziert wird und nur in geringerem Maße in Mikroglia. Zweitens haben wir 
in gemeinschaftlichen Bemühungen mikroglia-angereicherte und mikroglia-depletierte 
Fraktionen in APPPS1-Mäusen analysiert, wobei die letztere Fraktion hauptsächlich 
Astrozyten sowie Oligodendrozyten und, in einem geringeren Ausmaß, Neuronen enthielt, um 
die relative Induktion von ApoE-Protein in diesen Fraktionen mittels Massenspektrometrie zu 
vergleichen. In der Tat erzeugte die mit Mikrogliazellen angereicherte Fraktion mehr ApoE in 
APPPS1/Trem2+/+ im Vergleich zu APPPS1/Trem2-/- Mäusen. Darüber hinaus zeigten die an 
Mikrogliazellen depletierten Fraktionen in diesen Mäusen keine Trem2-abhängigen Effekte, 
was darauf hindeutet, dass ApoE unter gesunden physiologischen Bedingungen zwar 
hauptsächlich durch Astrozyten synthetisiert werden kann, Mikroglia jedoch während einer 
Entzündung zur gesamten ApoE-Produktion im Gehirn beitragen können. Drittens, zur 
Bestätigung dieser Befunde, verglich ich die Plaque-assoziierten ApoE-Spiegel und ihren Glia-
Ursprung in Mikroglia depletierten APPPS1 Mäusen mit den altersüblichen APPPS1-
Kontrollen. Bei Mikroglia-Depletion fehlte ApoE nicht nur weitgehend in den Plaques, 
sondern zeigte auch eine signifikante Reduktion der IBA1/ApoE-Kolokalisationsfärbung. Es 
wurden keine Veränderungen der GFAP/ApoE-Kolokalisationen im Vergleich zu den 
Kontrollen beobachtet, was darauf hindeutet, dass der ApoE-Gehalt in Plaques weitgehend von 
krankheitsassoziierten Mikroglia herführen kann. Um zu testen, ob diese präklinischen 
Ergebnisse auf den Menschen übertragen werden können, untersuchte ich Mikroglia, die sich 
um Aβ-Plaques herum ansammeln, und deren ApoE-Gehalt bei AD-Patienten mit 
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verschiedenen TREM2-Codierungsvarianten. AD-Patienten mit TREM2-Varianten zeigten im 
Vergleich zu AD-Fällen mit der üblichen TREM2-Variante unabhängig von ihrem APOE-
Genotyp eine beeinträchtigte Mikrogliazellen-Assoziation mit Plaques sowie verringerte 
ApoE-Spiegel. 
Zusammenfassend liefern meine Studien den ersten Beweis dafür, dass der Verlust der 
Trem2-Funktion nicht nur die frühe Plaquebildung aufgrund einer gestörten 
mikroglialen Phagozytose erhöht, sondern auch die Kinetik der Amyloidogenese 
während des Alterns verändert. Darüber hinaus fand ich heraus, dass ApoE-
Proteinspiegel in Plaque-assoziierten Mikroglia unter Krankheitsbedingungen auf eine 
Trem2-abhängige Weise induziert werden. Während der ApoE-Beitrag von Astrozyten 
nicht vollständig ausgeschlossen werden kann, reduzieren Mikroglia-Depletion bei 
Mäusen und TREM2-Codierungsvarianten bei AD-Patienten ApoE in Plaques drastisch, 
was wiederum den Aβ-Metabolismus beeinflussen kann. Diese Ergebnisse legen nahe, 
dass die TREM2-APOE-Wechselwirkung anfänglich als Schutzmittel zur Modulation 
der Aβ-Plaque-Beseitigung dienen kann, parallel dazu jedoch die Aβ-Pathologie 
verschlimmern kann. Daher muss bei jeder therapeutischen Strategie, die versucht, die 
Mikrogliafunktion zur Modulation der Aβ-Pathogenese zu beeinflussen, die 
Auswirkungen von TREM2 auf APOE berücksichtigt werden. 
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I. Introduction 
1 Alzheimer’s disease  
Alzheimer’s disease (AD) is a terminal, age-related neurodegenerative disease, which affects 
over 20 million people worldwide and is known to be the most common cause of dementia 
(www.alz.org/alzheimers-dementia). Given the accelerated aging of the population, the 
number of individuals with AD is predicted to increase dramatically and create a worldwide 
public health crisis (www.alz.org/alzheimers-dementia/facts-figures). AD is clinically 
distinguished by loss of memory and progressive decline in cognitive function. Current 
medications for AD only provide symptomatic relief by delaying cognitive decline, however 
there are no disease-modifying therapies available to intervene the course of AD dementia or 
delay its onset.  
 
Figure 1.1 Multifaceted pathology of AD. Amyloid-β (Aβ) plaques and tau aggregates are often found 
throughout the (A) AD brain, particularly in the temporal cortex upon post-mortem histological 
examination, compared to (B) healthy elderly brain. Ionized calcium binding adaptor molecule 1 
(IBA1)-positive microgliosis and glial fibrillary acidic protein (GFAP)-stained astrogliosis are often 
observed in AD. Arrows indicate areas of increased gliosis. Cortical and hippocampal brain areas are 
most commonly affected and begin to shrink with increasing severity of neurodegeneration as seen by 
enlarged ventricles in AD compared to healthy control. Red dotted area in the magnetic resonance 
imaging (MRI) scan shows significant hippocampal atrophy in AD patient compared to control. In vivo 
positron emission tomography (PET) images show increased Aβ and tau signal in AD compared to 
healthy cases. Similarly, increased 18-kDa translocator protein (TSPO) signal is observed due to 
increased gliosis and inflammation in the AD brain. (Adapted from (Higuchi et al., 2016)). 
Post-mortem AD brains present key histopathological hallmarks accompanied by widespread 
brain atrophy (Figure 1.1) (Braak and Del Tredici, 2011). These include aggregation and 
accumulation of extracellular Aβ plaques and intracellular tau neurofibrillary tangles (NFTs) 
(Figure 1.1). AD was initially considered a cell-autonomous neurodegenerative disorder, 
although Aβ and tau pathology is often accompanied by marked gliosis in AD patients and 
respective mouse models. In fact, Alois Alzheimer already illustrated the abnormal 
morphology of glial cells in the initial publication describing the disease (Alzheimer, 1907). 
Since then, extensive post-mortem immunohistochemical examinations illustrate abnormal 
protein aggregates that are often associated with activation of microglia and astrocytes 
(Ransohoff, 2016). Although AD is often accurately diagnosed only after death, recent 
biomarker and imaging studies indicate that AD pathology begins decades before the onset of 
clinical symptoms (Gonneaud et al., 2017, Insel et al., 2017, Suarez-Calvet et al., 2016a, 
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Suarez-Calvet et al., 2016b). Imaging modalities such as MRI provide detailed three-
dimensional structural information of the brain by using tissue characterisation with soft tissue 
contrast, while PET specifies functional and metabolic changes in the brain by detecting 
gamma rays emitted indirectly by a radioactive tracer (Zhang et al., 2017). Thus, a combination 
of PET/MRI has significantly improved our understanding of different stages of AD by 
measuring changes in Aβ and tau deposits as well as gliosis over time (Figure 1.1). Extensive 
neuroimaging studies involving a large cohort of AD patients at different disease stages imply 
that degrees of hippocampal atrophy, ventricular and whole-brain volumes can predict the 
disease progression (Fox et al., 2001, Gispert et al., 2016). To date, the cause of AD is not well 
understood. However, accumulating genetic and functional evidence strongly indicates an 
active role of brain innate immunity in AD pathogenesis and progression (Pimenova et al., 
2018). 
1.1 Early onset AD  
Aging is the greatest risk factor for sporadic AD (Guerreiro and Bras, 2015). Besides aging, 
environmental, epigenetic, and genetic factors contribute to the risk of developing AD. The 
majority of AD cases are sporadic with familial (FAD) cases accounting for less than 1% 
(Campion et al., 1999). This small percentage of autosomal dominant AD (ADAD) cases 
manifest with early dementia onset, typically between the age of 30 and 60 years old due to 
mutations in presenilin 1 (PS1), presenilin 2 (PS2) and amyloid precursor protein (APP). While 
presenilins are mainly known as the catalytic subunit of the γ-secretase complex, APP has 
several important physiological functions in neuronal plasticity, synaptic transmission, 
cognition and neuroprotection during brain development as well as in the mature and ageing 
brain (Muller et al., 2017, Richter et al., 2018, Rice et al., 2019, Haass and Willem, 2019). In 
the healthy brain, APP functions as a cell surface receptor-like protein or ligand and may 
mediate its effects from the cell surface or via its secreted proteolytic fragments, particularly 
secreted APPα (sAPPα) (Figure 1.2). However, APP mutations located within or immediately 
flanking the Aβ region of APPβ affect Aβ production or aggregation, for example by altering 
the proteolytic activity of β- and γ-secretases (Figure 1.2) (Citron et al., 1992). Mutations in 
components of the γ-secretase complex PS1 or PS2 also favour the amyloidogenic pathway by 
reducing the γ-secretase complex activity to increase Aβ42/40 ratio or by generating longer 
amyloidogenic peptides such as Aβ42 and Aβ43 (Saito et al., 2011, Kretner et al., 2016). 
Moreover, certain mutations in APP or PS do not necessarily affect Aβ production but may 
instead affect its hydrophobic properties and therefore its aggregation propensity and clearance 
(Tsubuki et al., 2003). For example, the London APP mutation (V717I) increases the Aβ40/42 
ratio by modifying the γ-secretase cleavage (Goate et al., 1991), while the Swedish mutation 
(K670N/M671L) enhances the β-secretase cleavage, thereby promoting Aβ production (Hardy 
and Selkoe, 2002). Additionally, the Icelandic APP mutation (A673T) based N-terminal to the 
β-secretase cleavage site not only reduces Aβ production, but also protects against AD (Jonsson 
et al., 2012). These findings suggest that Aβ plays an important role in the initiation and 
development of AD pathology. 
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Figure 1.2 Proteolytic processing of APP. APP is a type 1 transmembrane protein with the carboxyl 
terminus within the cytosol and amino terminus within the extracellular space. In the non-
amyloidogenic pathway, APP is processed consecutively by α- and γ-secretases to yield sAPPα, p3, and 
the APP intracellular domain (AICD). However in the amyloidogenic pathway, APP is first cleaved by 
membrane-bound endoprotease β-secretase to release a large fragment called sAPPβ. The remaining 
membrane bound C99 fragment is sequentially cleaved by γ-secretase to yield Aβ peptides. The longer 
Aβ peptides, for example Aβ42 and Aβ43, are the more hydrophobic and aggregation-prone species that 
are commonly found in Aβ core plaques. Amyloid plaque cores composed of fibrillar Aβ in a β sheet 
conformation are surrounded by a halo of diffuse Aβ.  
1.2 Late onset AD 
Genome wide association studies (GWAS), a methodology that compares allele frequencies of 
polymorphisms between cases and controls, have identified many genetic risk factors 
implicated in increasing susceptibility for late onset AD (LOAD). The majority of AD cases 
clinically manifest later than FAD, that is, after the age of 60 but is pathologically identical to 
FAD. In the non-AD brain, the Aβ peptide is cleared from the brain via several means: (1) 
enzymatic degradation (Carson and Turner, 2002), (2) secretion across the blood brain barrier 
(BBB) (Cirrito et al., 2005, Ma et al., 2018), (3) glymphatic clearance system (Jessen et al., 
2015), or (4) microglia phagocytosis (Lee and Landreth, 2010). However, LOAD cases often 
display deficits in Aβ clearance and Aβ production (Figure 1.3) (Mawuenyega et al., 2010, 
Selkoe, 2001). For example, apolipoprotein E (APOE) – the strongest genetic risk factor for 
LOAD - modulates Aβ clearance and aggregation isoform-dependently (Castellano et al., 
2011, Holtzman et al., 2000). The APOE gene resides on chromosome 19 with three common 
alleles present in the human population: ε2 (Cysteine 112, Cysteine 158), ε3 (Cysteine 112, 
Arginine 158) and ε4 (Arginine 112, Arginine 158). The ε4 allele is associated with an 
increased risk, whereas ε2 is relatively protective compared to the ε3 allele. A single copy of 
ε4 increases AD risk by ~3-fold, while two copies increases the risk by ~12-fold, thereby 
affecting the age of onset and disease severity significantly (Corder et al., 1993, Saunders et 
al., 1993). More than 50% of LOAD patients carry at least one copy of the ε4 allele. 
Homozygous ε4/ε4 individuals include 15% of LOAD cases, however only 2% of the healthy 
population are ε4/ε4 carriers (Farrer et al., 1997). Although carrying the ε4 haplotype does not 
 18 
necessarily guarantee that an individual will develop LOAD, the ε4 isoform appears to affect 
brain function associated with both altered neurological and metabolic functions decades prior 
to any clinical symptoms becoming obvious (Filippini et al., 2009, Michaelson, 2014) (further 
discussed in section 4.0).  
Over 50% of GWAS-identified risk factors are involved in microglial and innate immune cell 
function, some of which include ABCA7, ABI3, CD33, CLU, CR1, MS4A4A, and PLCγ2 
(Harold et al., 2009, Lambert et al., 2013, Naj et al., 2011, Sims et al., 2017, Hollingworth et 
al., 2011). Additionally, the triggering receptor expressed on myeloid cells type 2 (TREM2) 
significantly impacts the risk of LOAD with similar odds ratio to the single APOE ε4 allele 
(Guerreiro et al., 2013a). Innate immunity is an indispensible component in AD pathogenesis 
as chronic glial activation is a prominent feature accompanying pathological protein 
accumulation in the AD brain. Moreover, immune cells such as microglia and astroglia that 
react to disease-associated protein aggregates may not simply be bystanders, but may instead 
contribute to AD pathogenesis (Wyss-Coray and Rogers, 2012). For example, long-lasting 
inflammation may cause neuronal damage and death via several mechanisms, such as: (1) 
release of toxic substances including reactive oxygen species and nitric oxide, (2) enhanced 
expression of “eat-me” signals including phophatidylserine and calreticulin which induce 
phagoptosis, (3) activation of complement system to induce cell lysis, and (4) activation of 
inflammasomes (Shi and Holtzman, 2018). Thus, Aβ build-up due to impaired innate immune 
cell functions may serve as a driving force for disease progression by influencing 
neurodegeneration. 
1.3 Amyloid cascade hypothesis 
The amyloid cascade hypothesis is strongly supported by genetic evidence not only from FAD 
cases, but also because multiple copies of APP cause ADAD with cerebral amyloid angiopathy 
(CAA) (Rovelet-Lecrux et al., 2005) or Down’s syndrome (Delabar et al., 1987) with increased 
accumulation of Aβ peptides. The hypothesis proposes that excessive Aβ peptide 
accumulation, particularly of the longer, more aggregation-prone Aβ species, is the causative 
agent in AD pathology that sets of a series of downstream events that ultimately leads to 
dementia and neurodegeneration (Hardy and Selkoe, 2002, Selkoe, 1991, Hardy and Higgins, 
1992) (Figure 1.3). For example, the build-up of extracellular Aβ aggregates may result in 
increased oxidative and endoplasmic reticulum (ER) stress as well as disrupted ionic 
homeostasis, which may create an imbalance of phosphatases and kinases that stimulate the 
hyperphosphorylation of tau, enhance vascular and neuronal damage, and induce widespread 
neuroinflammation observed as the disease progresses (Hardy and Selkoe, 2002, Haass and 
Selkoe, 2007). However, the hypothesis has also been criticized as not all observations 
necessarily fit. For instance, early symptoms of dementia and neuronal loss have been more 
closely linked to amount of NFT deposits rather than Aβ plaques (Arriagada et al., 1992, 
Musiek and Holtzman, 2015). Additionally, Aβ plaques appear to be neurotoxic particularly in 
the presence of NFTs (Rapoport et al., 2002). These seemingly contradicting findings may be 
explained by the prerequisite of Aβ oligomers or deposits to be initially present to consequently 
trigger tau-mediated toxicity (Haass and Selkoe, 2007). Nonetheless, while rare variants in the 
microtubule associated tau-encoding gene have been linked to tauopathies, such as 
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frontotemporal dementia (FTD) (Hutton et al., 1998, Neumann et al., 2009), AD onset is 
primarily influenced by genetic variations affecting Aβ production (Hardy and Allsop, 1991, 
Hardy and Higgins, 1992). On the other hand, the presence of senile Aβ plaques in the absence 
of cognitive abnormalities suggests that Aβ may not necessarily initiate the downstream events 
but may instead be associated with aging (Bennett et al., 2006, Morris et al., 2010). Although, 
why would Aβ in AD patients act differently compared to healthy elderly cases? Several 
immune cell receptors expressed particularly on microglia in the brain are responsible for 
engulfing and degrading Aβ plaques. Many of these microglial receptors, including TREM2, 
have been recently linked to increased LOAD risk (discussed in section 1.2), suggesting that 
the difference in AD patients and healthy aging cases may be the failure of microglia to 
appropriately respond to the pathogenic Aβ. Therefore, the inability to remove the initial threat 
in time becomes increasingly destructive leading to overwhelming Aβ production as well as 
loss of microglial function (discussed in section 2). In parallel, the accumulating Aβ may 
trigger an inflammatory response leading to increased free reactive oxygen species and a 
cytokine profile that promotes neuroinflammation, synaptic degradation and 
neurodegeneration (Wyss-Coray and Rogers, 2012) (further discussed in section 2.0). Thus, 
the microglia-Aβ interaction may significantly impact AD onset and severity as a consequence 
of an imbalance between Aβ-peptide production and clearance. 
 
Figure 1.3 Schematic representation of the amyloid cascade hypothesis.  
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1.4 Mouse models of amyloid pathology  
As there are no efficient naturally occurring animal models for AD, the discovery of APP and 
PS mutations in AD gave rise to indispensable opportunities to study amyloidosis in transgenic 
mouse models harbouring these mutations (Götz et al., 2004, Sasaguri et al., 2017, LaFerla and 
Green, 2012). Using “humanised” mice carrying human APP and PS variants can be used to 
not only investigate Aβ pathology and associated disease phenotypes, but also the affinity of a 
drug designed to bind to the relevant human protein (Sasaguri et al., 2017, Webster et al., 
2014). Ideally, animal models of AD should entirely recapitulate the complete human 
pathological scenario, that is, synaptic dysfunction and loss, progressive cognitive decline, 
amyloid plaques and NFT deposition, inflammation, neuronal death as well as brain atrophy 
(Sasaguri et al., 2017). However, current models recapitulate only certain aspects of the 
disease. For example, even though many APP and PS1 mouse models exhibit extracellular Aβ 
deposits, reminiscent of plaques in the human AD brain, to date none of the amyloidogenic 
transgenic mouse models show aggregated tau deposits or neuronal loss in the brain. 
Several Aβ-depositing mouse models have been extensively studied, some of which include 
PDAPP (Games et al., 1995), Tg2576 (Hsiao et al., 1996), APP23 (Sturchler-Pierrat et al., 
1997), J20 (Mucke et al., 2000), TgCRND8 (Chishti et al., 2001), APP/PS1dE9 (Jankowsky 
et al., 2004) and APP/PS1 (Radde et al., 2006) among many others. Most amyloid mouse 
models currently available overexpress one or more of the FAD mutations such as the London 
or Swedish mutations. As a result, these mice develop substantial Aβ deposits between 6-11 
months of age, eventually displaying progressive plaque-associated gliosis and dystrophic 
neurites with age (Sasaguri et al., 2017). Certain APP transgenic mouse models, such as the 
Swedish mutation-overexpressing mice, show apparent behavioural deficits at a young age 
compared to wild-type (WT) mice. Even though PS1 mutations cause the majority of FAD 
cases (Karch et al., 2014), overexpression of mutant PS1 or a knock-in of the human gene 
mutation alone fails to induce Aβ pathology in mice. This may most likely be due to insufficient 
production of pathogenically longer Aβ species (De Strooper et al., 1995). Alternatively, the 
difference in three amino acids in murine Aβ1-42 sequence from human Aβ reduces the 
amyloidogenic potential of murine Aβ to self-aggregate as well as its degree of neurotoxicity 
(Chui et al., 1999, Guo et al., 1999, Schmitz et al., 2004, Xu et al., 2015). Thus, Aβ pathology 
in transgenic mouse models is only induced with the overexpression of both mutated human 
APP and PS, such as Tg2576 and PS1M146L (Holcomb et al., 1998), APPKM670/671NL and 
PSA246E (Borchelt et al., 1997), APP KM670/671NL and PS1 deltaE9/S290 (Jankowsky et 
al., 2004), APP KM670/671NL and PS1 L166P (Radde et al., 2006), and others.  
Overexpressing several transgenic insertions may destroy the endogenous gene loci (Saito et 
al., 2016) and overproducing APP fragments unrelated to Aβ may interact abnormally with 
cellular proteins leading to artefacts (Mitani et al., 2012, Saito et al., 2016). To overcome the 
drawbacks of APP overexpression paradigm, APP knock-in mice were generated to 
overproduce pathogenic Aβ42 without changing APP expression (Saito et al., 2014). For this, 
the authors inserted humanised Aβ region containing two or three APP mutations (Swedish 
KM670/671NL and Beyreuther/Iberian I716F mutations, respectively) into the endogenous 
murine APP gene resulting in increased Aβ plaque deposition and high Aβ40/42 ratio (Saito et 
al., 2014). The Beyreuther/Iberian mutation increases the Aβ40/42 ratio by 30-fold 
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(Lichtenthaler et al., 1999), which was later identified as an aggressive form of FAD in Iberia 
(Guerreiro et al., 2010). Although the APP knock-in model may offer an improved mouse 
model for FAD, the mice do not develop fibrillar core Aβ plaques until much later in age, with 
almost no vascular pathology compared to the APP and PS1 double transgenic mice. Thus, the 
APP overexpression and knock-in mice each independently present distinct advantages and 
disadvantages depending on the aim of the experiment. 
1.4.1 The APPPS1 mouse model 
APPPS1 mice (line 21) carry human transgenes for the Swedish APP mutation 
(K670N/M671L) and PS1 (L166P) mutation. Both genes are expressed under thymidine 1 
(Thy.1) promoter to ensure high levels of neuron-specific transgene expression in the postnatal 
brain (Radde et al., 2006). The human APP transgene is expressed approximately 3-fold higher 
than the endogenous murine APP, and mainly expressed in neocortical, hippocampal, and brain 
stem neurons. Consequently, APP overexpression results in roughly 3-fold increased Aβ 
generation compared to WT mice due to enhanced β-secretase cleavage (Radde et al., 2006). 
The aggressive PS1 L166P mutation, which causes onset of AD as early as 24 years of age 
(Moehlmann et al., 2002, Bentahir et al., 2006), favours the production of human Aβ42 over 
Aβ40, all of which increase with age (Li et al., 2016).  
 
Figure 1.4 Microglia clustering around Aβ plaques. Left: Aβ plaques (red) and microglia (brown) 
stained temporal cortex of an AD case. Scale bar - 100μm. Right: Aβ plaques (magenta) and microglia 
(green) stained in APPPS1 mouse cortex. Scale bar - 20μm. Insets show a higher magnification of the 
area indicated in white dotted boxes. (Experiments performed and imaged by S. Parhizkar). 
Amyloid plaque deposition starts in the neocortex at six weeks of age (Radde et al., 2006). 
Despite their small size, nearly 100% of the plaques are congophillic in nature. Deposits in the 
hippocampus appear at around three months of age in males and four months in females. 
Congophillic plaques are also observed in the striatum, thalamus and brain stem after five 
months of age. By eight months, these mice exhibit substantial plaque load with the majority 
of plaques consisting of a dense core surrounded by a diffuse halo, resembling plaques 
observed in the human AD brain (Figure 1.4). Tau-positive neuritic processes are present at 
later stages in proximity to dense cored plaques, however fibrillar tau inclusions fail to 
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accumulate (Radde et al., 2006). Moreover, microgliosis and astrogliosis are often observed in 
plaque-bearing regions similar to the AD brain (Figure 1.4). Additionally, cognitive 
impairments manifest around six to eight months of age, often presented by deficits in spatial 
learning and memorizing a maze task (Radde et al., 2006, Serneels et al., 2009). Neuron loss 
is largely absent in this mouse model, with only modest loss found in the granule cell layer of 
the dentate gyrus after 15 months of age (Rupp et al., 2011). 
Besides investigating Aβ pathology in the brain, the Aβ levels in cerebrospinal fluid (CSF) 
have also been extensively studied (Bacioglu et al., 2016, Maia et al., 2013). Aβ42 and Aβ40 
levels in CSF decrease with age by approximately 80% and 45%, respectively. This reduction 
in Aβ levels strongly correlates with increased Aβ aggregates depositing in the brain. 
Additionally, the total tau concentrations increase at six months, reaching a 5-fold increase by 
18 months of age (Maia et al., 2013). Altogether, these findings in the APPPS1 mouse model 
closely corroborate the amyloid pathology observed in AD patients (Figure 1.4), and therefore 
serve as a suitable system to study amyloidosis-related pathomechanisms allowing relatively 
rapid experimental readouts. 
1.5 The prion paradigm – Propagation of proteopathic seeds 
Numerous studies on the role of protein aggregation in neurodegenerative diseases have 
speculated that the essential cause of neuronal dysfunction and death may result from 
cumulative protein misfolding and aggregation (Goedert et al., 2017, Walker and Jucker, 
2015). Although neurodegenerative diseases such amyotrophic lateral sclerosis (ALS), 
Parkinson’s disease, FTD and AD present different pathological and clinical characteristics, 
the diseases share a central pathogenic mechanism: the seeded aggregation of disease-specific 
proteins (Prusiner, 2012, Jucker and Walker, 2013, Guo and Lee, 2014). The prion paradigm 
proposes that assemblies of misfolded protein act as seeds for the template misfolding of other 
uncorrupted molecules (Figure 1.5). The seeds may be the agents by which the aggregates 
proliferate and spread elsewhere in the brain, once again initiating seeding and thereby 
sustaining the disease process (Prusiner, 1984, Gajdusek, 1994). The hypothesis arose from 
decades of research on a group of proteinaceous infectious diseases, known collectively as 
transmissible spongiform encephalopathies (Collins et al., 2004). Prusiner and colleagues 
showed that prions are infectious agents consisting of abnormally folded prion protein (PrP) 
(Prusiner, 1982). Initially, prion diseases were thought to be present in humans only, e.g. 
Creutzfeldt-Jakob disease, Gerstmann-Sträussler-Scheinker disease, kuru and fatal insominas. 
However, during the years several rare human spongiform encephalopathies were found to be 
transmissible to nonhuman primates (Gajdusek, 1977), for example scrapie in sheep, chronic 
wasting disease of deer and elk, bovine spongiform encephalopathy, and others (Caughey et 
al., 2009, Prusiner, 1998). Prion diseases are best known for their infectivity, however they can 
also be genetically heritable or sporadic in origin (DeArmond and Prusiner, 1995), similar to 
AD. Under normal conditions, the cellular prion protein (PrPC) assumes a nonpathogenic α-
helical conformation with little β-sheet. The disease manifests when PrPC molecules misfold 
into a shape abnormally enriched in β-sheet – similar to Aβ peptide in AD, and propagate 
through the nervous system after self-assembly. This corrupted form of PrP is called PrP-
scrapie (PrPSc). An important characteristic of misfolded prion protein is its enhanced potential 
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to form amyloid, that is, abnormal quantities of fibrillar protein (DeArmond and Prusiner, 
1995). Thus, similarities in biophysical properties of amyloidogenic proteins suggest that 
diseases characterised by abnormal protein deposition share certain etiological mechanisms 
(Gajdusek, 1994, Lansbury, 1997, Prusiner, 1998, Trojanowski and Lee, 1998, Goedert et al., 
2017).  
 
Figure 1.5 Prion-like template and seeding. A small portion of pathological seeds act as a template 
to induce misfolding and aggregation of the soluble protein, similar to the way amyloid fibril formation 
is accelerated upon addition of pre-formed pathological seeds in vitro (Harper et al., 1997, Hasegawa 
et al., 1999). The initial lag phase of the primary nucleation step follows a secondary nucleation step, 
during which existing fibrils are broken down into smaller fragments that become the building blocks 
for further seeding of soluble peptide monomers. Therefore, the second step not only depends on the 
rate at which the fibrils are created but also the availability of the soluble peptide monomers (Jarrett 
and Lansbury, 1993, Knowles et al., 2009). Thus, new preformed seeds can facilitate the formation of 
larger multimeric amyloid fibrils. (Adapted from (Goedert, 2015)).  
1.5.1 Amyloid seeding 
AD is not a classic prion disease, but shares several similarities. Aβ peptide multimerisation is 
long known to be an early and central process in the pathogenic cascade in AD (Selkoe, 2003, 
Hardy and Selkoe, 2002). However, little is known about the mechanisms that govern the 
initiation of Aβ aggregation and deposition in vivo. In the late 80’s, several groups performed 
inoculation experiments to test the hypothesis that AD, like spongiform encephalopathies, was 
transmissible (Goudsmit et al., 1980, Baker et al., 1993). Baker et al showed that intracerebral 
injections of AD brain homogenate into marmoset monkeys led to increased senile plaque load, 
however only after a long incubation period of approximately six to seven years. Moreover, 
the inductive agent as well as the mechanism of action remained unknown (Baker et al., 1993). 
As the first APP transgenic mouse models became available (Games et al., 1995, Hsiao et al., 
1996, Sturchler-Pierrat et al., 1997), Aβ seeding experiments were carried out to determine 
whether Aβ deposits could be generated de novo in a prion-like manner. Brain extracts from 
autopsy-derived AD patients and controls were stereotaxically injected into the hippocampal 
formation and overlying neocortex in young, predepositing APP-transgenic mice (Meyer-
Luehmann et al., 2006, Walker et al., 2002, Kane et al., 2000). Three to five months post-
injection, fibrillar Aβ deposits increased significantly at a point when the transgenic model 
would not yet have begun to develop endogenous Aβ plaques. Since then, the seeding paradigm 
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has been widely used in many different APP transgenic mice such as, Tg2576, APP23, APPPS1 
and 5xFAD as an inoculation model to induce Aβ aggregation and cerebral amyloidosis (Watts 
et al., 2014, Langer et al., 2011, Meyer-Luehmann et al., 2006, Kane et al., 2000, Morales et 
al., 2012, Rasmussen et al., 2017, Ziegler-Waldkirch et al., 2018). Additionally, the amyloid 
seeding model provides the unique opportunity to study plaque formation within a very defined 
and early time window. Furthermore, Aβ seeding activity persists for at least six months in the 
brain, even in the absence of template replication from host-derived Aβ (Ye et al., 2015a). The 
longevity of Aβ seeds in vivo suggests that they may act as resilient prion-like protein, which 
may provide novel insights into changes in brain activity preceding the onset of dementia in 
AD. 
The amyloid seeding model not only necessitates a donor extract containing Aβ seeds but also 
a host that can generate seeding-capable Aβ plaques. For example, injecting brain extracts from 
non-transgenic mice or non-AD control donors that lacked Aβ deposition failed to seed plaque 
formation (Meyer-Luehmann et al., 2006, Kane et al., 2000). Growing evidence supports the 
existence of variant structural strains of Aβ seeds, like tau (Falcon et al., 2015, Goedert, 2015) 
and PrP (Aguzzi et al., 2007, Collinge and Clarke, 2007, Prusiner, 2013). Injecting Aβ-rich 
brain extracts, which included Aβ monomers, oligomers, and larger multimeric Aβ species, 
from aged APP transgenic donor of the same strain as the host mice displayed a strain-specific 
seeding pattern (Meyer-Luehmann et al., 2006, Watts et al., 2011, Heilbronner et al., 2013). 
Moreover, different molecular Aβ conformations linked to their functionality have been 
detected in vivo. This was first observed immunohistochemically, which showed 
morphological changes in the Aβ staining pattern depending on the characteristics of both the 
APP-transgenic host and donor seeding extract (Meyer-Luehmann et al., 2006). Additionally, 
Aβ conformation-specific oligothiophene dyes confirmed that the molecular attributes of Aβ 
aggregates show intersubject variability among FAD and sporadic AD patients (Rasmussen et 
al., 2017, Condello et al., 2018). 
The extent of Aβ seeding is directly proportional to concentration of the injected brain extract 
(Meyer-Luehmann et al., 2006, Fritschi et al., 2014b). Additionally, the characteristics and rate 
of induced Aβ pathology further depend on the brain area injected, with strongest deposition 
in the entorhinal cortex and the hippocampal molecular layer, granular cell layer as well as the 
subgranular cell layer in the dentate gyrus (Walker et al., 2002, Meyer-Luehmann et al., 2006, 
Eisele et al., 2009). Ziegler-Waldkirch and colleagues were the first to show substantial 
neuronal death following Aβ deposition in vivo (Ziegler-Waldkirch et al., 2018). Using the 
amyloid seeding model, the authors found a dramatic decrease in proliferation and 
neurogenesis in the granular cell layer of dentate gyrus in two APP transgenic mouse models. 
These regions are also severely affected in aging transgenic mice under normal conditions 
(Radde et al., 2006). The selective vulnerability of these brain regions indicates that the starting 
point of the seeding cascade is crucial for the route or spread of pathology (Eisele et al., 2009, 
Meyer-Luehmann et al., 2006, Ziegler-Waldkirch et al., 2018). Furthermore, after injecting the 
seeding-competent brain extract into the hippocampus, Aβ deposits begin to appear in other 
brain regions throughout the hippocampal formation (Eisele et al., 2009) and limbic 
connectome over time (Ye et al., 2015b). As the limbic connectome is a major source of 
neocortical communication with the hippocampal formation and entorhinal cortex (Suh et al., 
 25 
2011), these studies suggest that seeded Aβ aggregates traffic along neuronal pathways to 
spread pathology through the brain, similar to the cell-to-cell transmission model suggested in 
prion diseases (Lee et al., 2010). However, whether this occurs by random diffusion or by 
active, cell-specific uptake and transport is yet to be determined in vivo.  
Seeding most likely occurs due to the nature of Aβ deposits rather than additional factors that 
may indirectly stimulate Aβ aggregation, e.g. a virus or an immune response to the foreign 
brain extracts. To date, the seeding factors remain unknown; however several studies indicate 
that Aβ itself may drive the mechanism to a large extent (Heilbronner et al., 2013, Langer et 
al., 2011, Fritschi et al., 2014a, Fritschi et al., 2014b). Disrupting the amyloid-inducing activity 
of the injected brain extract by heating, reduced the Aβ induction (Meyer-Luehmann et al., 
2006). Additionally, denaturation of brain extracts by formic acid treatment or co-inoculation 
of anti-amyloid antibody abolished the seeding effect (Meyer-Luehmann et al., 2006, Duran-
Aniotz et al., 2014). These findings support the direct role of Aβ as the seeding agent. 
Preparation of synthetic Aβ40, Aβ42 or a mixture of both failed to induce detectable Aβ 
deposition (Meyer-Luehmann et al., 2006) unless the concentration was increased 10-fold with 
a longer incubation period (Stohr et al., 2012). Of note, the seeding potency of Aβ38 or Aβ43 
found in AD patients has not been reported. Furthermore, amyloid seeding has been attempted 
in an ex vivo hippocampal slice culture model, however it appears to be sustainable only upon 
frequent exposure to high levels of synthetic Aβ (Novotny et al., 2016), similar to PrP seeding 
potency (Miller et al., 2013, Wang et al., 2010). Moreover, ASC-deficient APP/PS1deltaE9 
display reduced seeding and spreading of Aβ, suggesting that the secreting adaptor protein 
ASC specks found in the core of amyloid plaques may play an active role in initiating cross-
seeding of Aβ plaques (Venegas et al., 2017).  
The seeding model has influenced other research fields, such as the aggregation and spreading 
of tau (Guo et al., 2016, Clavaguera et al., 2013), α-synuclein (Volpicelli-Daley et al., 2011, 
Luk et al., 2012) or TAR DNA-binding 43 protein found in frontotemporal lobar degeneration 
cases (Porta et al., 2018). Additionally, it has been used as an in vivo model for cross-seeding 
studies to investigate the interactions between amyloid and other proteopathic co-pathology 
such α-synuclein, or tau (Gotz et al., 2001, Bachhuber et al., 2015, Guo et al., 2013, He et al., 
2018, Venegas et al., 2017, Bolmont et al., 2007, Rasmussen et al., 2017). The seeding model 
has also been used to test treatment options such as immunization (Meyer-Luehmann et al., 
2006) or environmental enrichment as a non-pharmacological approach (Ziegler-Waldkirch et 
al., 2018). Finally, recent studies suggest that microglia may contribute to the transport and 
processing of seeds in a disease stage-dependent manner (Asai et al., 2015, Venegas et al., 
2017). 
2. Microglia and AD 
Microglia constitute approximately 10% of the total glial population in the healthy adult brain. 
Together with meningeal, choroid plexus, and perivascular macrophages, microglia 
compromise the brain myeloid cell population that plays a pivotal role in the CNS immune 
response and homeostasis. As the main innate immune cells of the CNS, microglia represent 
the first line of immunological defence by constantly surveying their microenvironment for 
signs of damage or debris allowing them to respond rapidly to focal injury or invading 
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pathogens (Davalos et al., 2005, Mazaheri et al., 2017). Microglia have several functions in 
the developing CNS, including (1) axon growth and synaptogenesis, (2) synaptic pruning, (3) 
angiogenesis, (4) support of neurogenesis, (5) recognising and responding to abnormal events 
including focal injury or neuropathological insults such as Aβ plaques, and (6) apoptosis and 
phagocytosis (Ransohoff, 2016). These functions are central to disease progression and 
modulation because chronic glial activation is a prominent feature of aging and often goes 
hand-in-hand with pathological protein accumulation as well as cell death, both of which 
constitute central characteristics of neurodegeneration. Although microglia’s response to injury 
is usually beneficial, it may also be detrimental, especially in chronic inflammation observed 
in AD (Hickman et al., 2008, Lucin and Wyss-Coray, 2009). 
2.1 Disease-associated microglia 
Depending on their microenvironment, microglia were considered to be selective to two states: 
resting or activated. Anti-inflammatory ramified microglia were described as resting, or M2, 
often observed during healthy physiological conditions and morphologically characterised by 
long processes and a small cell body. In contrast, the M1 activated amoeboid microglia were 
illustrated as hypertrophied cell bodies with short processes, and characterised by production 
of pro-inflammatory cytokines and nitric oxide (Wyss-Coray and Rogers, 2012). Ramified 
microglia were found throughout plaque-free brain regions, whereas the amoeboid microglia 
were typically associated with senile plaques (Brawek et al., 2014). However, recent advances 
in transcriptomics (Butovsky et al., 2014, Hammond et al., 2018, Keren-Shaul et al., 2017, 
Mazaheri et al., 2017, Krasemann et al., 2017) indicate that the M1/M2 dichotomy do not truly 
reflect the heterogeneous microglial populations present in disease-associated inflammation. 
Comprehensive single-cell RNA sequencing analysis of AD, ALS and aging mouse models 
show that microglia are present in a continuum of distinct phenotypes that are highly dependent 
on their spatiotemporal context (Kang et al., 2018, Hammond et al., 2018, Keren-Shaul et al., 
2017). For example, microglia heavily cluster around Aβ plaques in both mice and humans 
(Figure 1.3) (Meyer-Luehmann et al., 2008, Serrano-Pozo et al., 2013, Parhizkar et al., 2019) 
and modulate Aβ pathogenesis (further discussed in 3.3.1). These subset of microglia are called 
disease-associated microglia (DAM) (Keren-Shaul et al., 2017) or microglia of 
neurodegenerative phenotype (MGnD) (Krasemann et al., 2017). While DAM markers such as 
Clec7a, Cd68 and Cst3 are upregulated during disease conditions, homeostatic microglial 
markers such as P2ry12, P2ry13, and Cx3cr1 are downregulated (Keren-Shaul et al., 2017, 
Masuda et al., 2019). DAM typically display upregulation of genes involved in pathways 
triggering phagocytosis, migration and chemotaxis, as well as lysosomal and lipid metabolism 
such as ApoE, Lpl, Dap12, and Trem2 (Kang et al., 2018, Keren-Shaul et al., 2017, Krasemann 
et al., 2017, Mazaheri et al., 2017, Hammond et al., 2018, Masuda et al., 2019), all of which 
are well-known AD risk factors (Lambert et al., 2013).  
3. Triggering Receptor Expressed on Myeloid Cells 2 
TREM2 belongs to a family of innate immune receptors referred to as triggering receptors 
expressed on myeloid cells (Bouchon et al., 2000). In humans, the TREM2 gene is located on 
chromosome 6p21.1 or 17C in mouse and encodes a 230 amino acid glycoprotein. Many of the 
TREM and TREM-like (TREML) genes such as TREM1, TREML1, TREM2, TREML2, 
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TREML3, and TREML4 are conserved in mice and humans with only Trem3 and Trem6 unique 
to mice and TREML3 to humans. TREM2 is a type 1 cell surface transmembrane glycoprotein, 
and consists of an extracellular V-type immunoglobulin (Ig)-like domain as well as a short 
cytoplasmic tail (Figure 1.6) (Bouchon et al., 2000). It is selectively expressed on microglia in 
the brain (Sessa et al., 2004, Neumann and Takahashi, 2007), but also abundantly found in the 
periphery in a subgroup of myeloid cells, including bone osteoclasts, dendritic cells, alveolar 
and peritoneal macrophages, granulocytes and Kuppfer cells (Bouchon et al., 2001, Cella et 
al., 2003, Paloneva et al., 2003, Colonna and Wang, 2016). Trem2 expression levels increase 
with aging (Jay et al., 2015, Guerreiro and Hardy, 2013, Jiang et al., 2014, Brendel et al., 2017) 
and vary depending on the particular region of the CNS, with a higher expression in the white 
matter and hippocampus in the brain (Chertoff et al., 2013, Forabosco et al., 2013). High levels 
of Trem2 expression were reported in CD45-expressing cells (Jay et al., 2015, Savage et al., 
2015), suggesting that Trem2-expressing cells could be of a peripheral origin and may be found 
in the brain due to infiltrating monocytes. However, these findings were later disputed using 
parabiosis experiments in AD mouse model reporting that Trem2-expressing cells were mainly 
resident microglia rather than infiltrating monocytes (Wang et al., 2016). DAM often display 
elevated Trem2 expression in AD, ALS, and aging mouse models (Keren-Shaul et al., 2017, 
Krasemann et al., 2017). Keren-Shaul and colleagues revealed that DAM activation occurs in 
a Trem2-dependent manner during which microglia acquire a phagocytic phenotype associated 
with synthesis and degradation of lipids (Keren-Shaul et al., 2017). Moreover, microglia appear 
to be locked in a homeostatic state with impaired chemotaxis and reduced responses to neuronal 
injury in Trem2-deficient mice (Mazaheri et al., 2017).  
TREM2 binds to multiple ligands including microbial products, phospholipids, as well as 
zwitterionic and anionic lipids released during neuronal and glial damage to activate TREM2 
signalling (Figure 1.6). TREM2 mutations appear to blunt the signalling activity, suggesting 
that the positively charged arginine residue may be critical for initiating TREM2 signalling. 
Other ligands include nucleic acids, proteoglycans as well as heat shock protein 60 (Kober et 
al., 2016), which play an active role in phagocytosis (Stefano et al., 2009). Additionally, 
specific lipid species initiate TREM2 signalling, either as a lipoprotein complex or components 
of a cellular membrane (Cannon et al., 2012, Poliani et al., 2015, Song et al., 2016, Wang et 
al., 2015). For example, TREM2 binds to high-density lipoproteins (HDL), low-density 
lipoproteins (LDL) as well as apolipoproteins (Apo), such as ApoA1, ApoA2, ApoB, ApoE 
and ApoJ (also known as clusterin) in vitro (Yeh et al., 2016, Atagi et al., 2015, Bailey et al., 
2015, Song et al., 2016). ApoE lipidation does not appear to be essential for ApoE-TREM2 
binding to occur (Atagi et al., 2015, Bailey et al., 2015, Jendresen et al., 2017), although Yeh 
and colleagues reported that ApoE lipidation augmented this interaction (Yeh et al., 2016). 
Moreover, TREM2 appears to bind to all ApoE isoforms with similar affinities (Atagi et al., 
2015, Bailey et al., 2015). 
TREM2 is shuttled to and from the plasma membrane via the secretory pathway, that is, the 
trans-Golgi network (Prada et al., 2006, Varnum et al., 2017), endosomes (Raha et al., 2017) 
and exocytic vesicles (Prada et al., 2006). TREM2 undergoes maturation by N-linked 
glycosylation during this transport process (Park et al., 2015), however the biological relevance 
of these modifications remains unknown. Full-length membrane bound TREM2 undergoes 
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proteolytic processing by a disintegrin and metalloproteinases (ADAM) α-secretases,  
ADAM10 or ADAM17, which results in ectodomain shedding between H157 and S158 
residues generating a soluble form of TREM2 (sTREM2) (Figure 1.6) (Feuerbach et al., 2017, 
Kleinberger et al., 2014, Schlepckow et al., 2017, Thornton et al., 2017, Wunderlich et al., 
2013). This cleavage terminates TREM2 signalling and its downstream effector functions. 
Interestingly, p.H157Y was recently identified as an AD risk variant (Jiang et al., 2016), and 
shows increased sTREM2 levels, reduced cell surface TREM2 as well as impaired 
phagocytosis in vitro (Schlepckow et al., 2017). 
 
Figure 1.6 TREM2/DAP12 signalling. (A) TREM2 binds to several ligands, and signals through its 
Ig-like V-type domain. The positively charged conserved lysine residue on TREM2 transmembrane 
region (amino acid 186) electrostatically interacts with negatively charged aspartic acid residue in 
DNAX-activating protein of 12 kDa (DAP12). Src kinase phosphorylates the DAP12 
immunoreceptor tyrosine-based activation motifs (ITAM). This phosphorylation recruits and 
activates spleen tyrosine kinase (Syk), which triggers downstream effectors including extracellular 
signal-regulated kinases (ERK), phosphoinositide 3-kinase (PI3K), phospholipase C-γ (PLCγ) and Vav. 
Subsequent intracellular Ca2+ efflux and actin cytoskeletal reorganisation promotes microglial functions 
such as motility and phagocytosis. TREM2 undergoes sequential proteolytic processing by ADAM 10 
or 17 resulting in ectodomain shedding of sTREM2. The remaining TREM2 transmembrane domain is 
subsequently cleaved by γ-secretase, releasing a C-terminal fragment (CTF) (Glebov et al., 2016, 
Wunderlich et al., 2013). TREM2 cleavage by ADAMs terminates the downstream signalling cascade. 
(B) The receptor for sTREM2 is unknown. The ectodomain shedding appears to activate PI3K, ERK 
and nuclear factor (NF)-κB pathways and enhances several microglial functions related to phagocytosis. 
(Adapted from (Konishi and Kiyama, 2018)). 
sTREM2 is readily found in in biological fluids such as serum and CSF in both mice and 
humans (Henjum et al., 2016, Kleinberger et al., 2017, Kleinberger et al., 2014, Wunderlich et 
al., 2013). CSF sTREM2 levels are thought to reflect the degree of microglial activation in the 
brain during disease progression (Heslegrave et al., 2016, Piccio et al., 2016) as well as the 
severity of brain atrophy due to its association with neuronal injury markers (Suarez-Calvet et 
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al., 2016b). Interestingly, CSF sTREM2 levels peak specifically during the early symptomatic 
stages of AD (Suarez-Calvet et al., 2016a), suggesting that sTREM2 may be a biomarker for 
not only disease severity but also cognitive decline that manifests in the earlier stages of AD 
(Jiang et al., 2014).  
3.1 TREM2/DAP12 and Nasu Hakola disease 
DAP12 belongs to the type 1 transmembrane adapter protein family (Wilson et al., 2000). It is 
abundantly expressed on immune cells such as natural killer cells, myeloid cells and 
neutrophils, and forms an ITAM-containing disulphide-linked homodimer (Figure 1.6). 
DAP12 itself is thought to have no ligand-binding capability due to its short extracellular 
domain (Lanier, 2009). To initiate an intracellular signalling cascade, TREM2 interacts with 
DAP12 within the transmembrane region through an electrostatic association (Bouchon et al., 
2000), which triggers a downstream signalling event regulating cell migration and survival, 
phagocytosis or cytokines release (Figure 1.6) (Colonna et al., 2007). Homozygous loss-of-
function mutation in TREM2 or DAP12 leads to a rare neurodegenerative disease associated 
with leukodystrophy, osteoporosis and a presenile form of frontal lobe dementia called Nasu 
Hakola disease (NHD, also known as polycystic lipomembranous osteodysplasia with 
sclerosing leukoencephalopathy, PLOSL) (Klunemann et al., 2005, Paloneva et al., 2001, 
Paloneva et al., 2002). To date, 11 TREM2 mutations have been reported to cause NHD, some 
of which include p.W78X, p.W44X, p.K186N, and p.D134G (Paloneva et al., 2002). 
Additionally, amyloid PET imaging revealed extensive Aβ pathology in a patient carrying the 
p.Q33X TREM2 variant (Ghezzi et al., 2017), which is more commonly found in FTD patients 
(Guerreiro et al., 2013b). Moreover, NHD patients develop bone cysts as early as the second 
decade of life, with dementia manifesting due to atrophy of the corpus callosum and frontal 
lobe regions. Other pathological changes include loss of myelin, gliosis, and enlarged brain 
ventricles, which also affect motor functions. As a result, NHD patients perish as early as the 
late fourth decade of life. Currently there are no NHD mouse models available, however 
Trem2- or Dap12-deficient mice display similar phenotypes including impaired myelination, 
reduced amyloid plaque-associated microglia and increased accumulation of diffuse Aβ 
plaques (Mazaheri et al., 2017, Wang et al., 2015, Keren-Shaul et al., 2017, Wang et al., 2016, 
Yuan et al., 2016, Parhizkar et al., 2019, Cantoni et al., 2015, Piccio et al., 2007, Kaifu et al., 
2003, Nataf et al., 2005). Moreover, TREM2 expression appears to be severely downregulated 
in dendritic cells from NHD patients, suggesting that disrupted TREM2 expression or 
signalling may be responsible for NHD symptoms.  
3.2 TREM2 and FTD 
Heterozygous or homozygous TREM2 coding variants such as p.T66M (Guerreiro et al., 
2013b, Le Ber et al., 2014), p.W198X (Giraldo et al., 2013), p.Q33X and p.Y38C (Guerreiro 
et al., 2013b) are associated with FTD. Although the p.T66M and p.Y38C heterozygous 
variants are found in AD patients, they are more commonly associated with FTD (Guerreiro et 
al., 2013b, Jonsson and Stefansson, 2013). Other AD-associated TREM2 variants such as 
p.T96K, p.L211P and p.R47H also increase the risk of developing FTD (Thelen et al., 2014, 
Rayaprolu et al., 2013). The p.T66M and p.Y38C mutations that reside in the Ig-like domain 
are misfolded in the ER (Kober et al., 2016, Park et al., 2015) and show impaired cell surface 
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trafficking (Kleinberger et al., 2014, Song et al., 2017), which may explain how TREM2 loss-
of-function affects FTD-like syndrome (Guerreiro et al., 2013b). Additionally, the 
glycosylation pattern of these mutations is also affected indicating impairment in maturation 
that could affect TREM2 function (Park et al., 2015).  
Knocking in p.T66M missense mutation in mice showed a gene dose-dependent reduction in 
sTrem2 in the brain, serum, and CSF due to ER retention of mutant immature sTrem2 
(Kleinberger et al., 2017). Decreased cell surface Trem2 resulted in loss of Trem2 function as 
observed by a decline in phagocytic ability of bone marrow-derived macrophages as well as 
reduction in TSPO and fluorodeoxyglucose (FDG) PET, which are indicative of decreased 
inflammation and impaired brain glucose metabolism or cerebral blood flow respectively. 
Interestingly, the p.T66M knock-in model also revealed evidence of poor removal of myelin 
debris with aging as observed by increased microglial nodules throughout the brain 
(Kleinberger et al., 2017). Although no bone-related pathology was observed in these mice, 
the model may help address several important questions such as how cerebral blood flow 
affects TREM2 maturation and whether sTREM2 or full length TREM2 may influence 
hypometabolism and neuronal activity in the brain in a cell-autonomous manner. Moreover, it 
may serve as an essential loss of Trem2 function model, which may be more suitable for 
comparing the clinical situation than manipulating gene expression, as is currently typical. 
3.3 TREM2 and AD 
Although TREM2 variants are rare with allele frequencies below 1%, several heterozygous 
TREM2 variants are found to confer higher AD risk including p.R47H, p.R62H, p.D87N, 
p.H157Y, p.T96K, p.W191X, p.L211P and R136Q (Bonham et al., 2017, Guerreiro et al., 
2013a, Jiang et al., 2016, Jin et al., 2014, Jin et al., 2015, Jonsson et al., 2013). The TREM2 
variants include early stop sites and ectodomain mutations, which consequently produce 
partially or non-functional protein (Giraldo et al., 2013). The p.R47H variant found more 
commonly in European and North American populations increases the risk of LOAD by 
approximately 3-fold, with similar odds ratio to single APOE ε4 allele (Guerreiro and Hardy, 
2013, Lill et al., 2015). Additionally, it is associated with higher total tau and phosphorylated 
tau in CSF (Cruchaga et al., 2013). The p.R47H variant has since then been confirmed to be 
associated with both early onset AD and LOAD in various case populations independent of the 
APOE ε4 risk variant (Jin et al., 2014, Pottier et al., 2013, Ruiz et al., 2014, Sims et al., 2017). 
LOAD patients with the p.R47H variant present an earlier onset of disease symptoms including 
faster cognitive decline (Slattery et al., 2014, Del-Aguila et al., 2018).  
While NHD-associated TREM2 variants impact protein expression, stability, folding and 
transport, the AD-associated TREM2 variants seem to impact the efficiency of TREM2 
signalling (Kleinberger et al., 2014, Ma et al., 2016, Song et al., 2016, Kober et al., 2016). 
Moreover, p.R47H variant AD patients show impaired microglial clustering around plaques 
(Yuan et al., 2016, Parhizkar et al., 2019), resulting in larger, more diffuse plaques (Yuan et 
al., 2016). Reduced plaque-surrounding microglia was also recently reported in 5xFAD mice 
overexpressing human p.R47H TREM2 but lacking endogenous expression of murine Trem2 
(Song et al., 2018). The microglial pathology the p.R47H mice were comparable to Trem2-
deficient 5xFAD mice, suggesting that the mutation causes a loss-of-function (Song et al., 
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2018). Murine p.R47H Trem2 knock-in also confirmed loss-of-function effects as a result of 
reduced Trem2 mRNA and protein production (Cheng-Hathaway et al., 2018). However, 
Trem2 haploinsufficieny appeared to be an artefact introduced by CRISPR resulting in atypical 
splicing of exon 1 and 2 in the p.R47H murine mutation, which was otherwise not observed in 
humans carrying the p.R47H coding variant (Xiang et al., 2018). These findings highlight the 
need to determine how different TREM2 variants influence alternative splicing and their 
functional consequences.  
3.3.1 TREM2, microglia function and Aβ pathology 
Microglia play an active role in regulating amyloid pathology by phagocytosis. However, the 
inconsistent results from microglia depletion studies using APP transgenic mice raise a critical 
question: At which disease stage does microglia most efficiently restrain amyloidogeneisis? 
Microglia depletion in vivo has shown that the timing and duration of microglia interaction 
with amyloid pathology plays an important role in its phagocytic abilities. Herpes simplex virus 
thymidine kinase (HSTK) is also known as a suicide gene as it converts ganciclovir (GCV) 
into toxic DNA replication inhibitors that results in cell death (Czako and Marton, 1994). Thus, 
expressing HSTK on a CD11b promoter, which is expressed in macrophages and microglia, 
results in microglia depletion upon GCV treatment in APPPS1 mice crossed with HSTK-
expressing mice (Grathwohl et al., 2009). Similarly, treating 5xFAD mice with macrophage 
colony stimulating factor 1 receptor (CSFR1) inhibitor results in microglia depletion 
(Spangenberg et al., 2016). Both microglia depletion systems do not affect plaque burden after 
onset of Aβ pathology (Spangenberg et al., 2016, Grathwohl et al., 2009). However, depleting 
microglia by CSFR1 inhibition prior to Aβ deposition dramatically reduced plaque pathology 
in 5xFAD mice (Sosna et al., 2018), suggesting that microglia may be involved in the initial 
seeding stage of plaque formation. Thus by eliminating newly seeded plaques, Trem2 may 
have protective functions at least early during amyloidogenesis (Parhizkar et al., 2019). 
A protective function of TREM2 is also supported by disease-associated TREM2 variants 
causing a loss-of-function (Abud et al., 2017, Kleinberger et al., 2017, Kleinberger et al., 2014, 
Song et al., 2018, Yeh et al., 2016). Trem2 haploinsufficiency or total genetic ablation reduces 
plaque-associated microglia (Jay et al., 2015, Wang et al., 2015, Ulrich et al., 2014), suggesting 
that Trem2 signalling is required to activate and recruit microglia to the plaques. Additionally, 
transcriptomic analyses of plaque-surrounding microglia show major changes in their 
molecular markers related to chemotaxis, proliferation, response to wounding and locomotion, 
compared to microglia that retain a homeostatic profile when no plaques are present 
(Krasemann et al., 2017, Mazaheri et al., 2017). Thus, Trem2-expressing microglia appear to 
be essential for promoting microglial association to plaques and constitutes a major population 
of DAM in Aβ-depositing mouse models (Keren-Shaul et al., 2017, Krasemann et al., 2017). 
Impaired microglial clustering around plaques have also been reported in AD cases with 
different TREM2 variants (Parhizkar et al., 2019, Yuan et al., 2016). Additionally, loss of 
Trem2 function shows increased seeding of early plaque deposits, most likely due to impaired 
Aβ clearance by microglia (Parhizkar et al., 2019). The inability of microglia to cluster around 
Aβ results in enlarged and more diffused plaques, which appear as star-shaped fibrils (Yuan et 
al., 2016, Wang et al., 2016). Such changes in plaque morphology as well as neuritic plaques 
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were also observed in AD patients carrying the p.R47H variant, similar to that observed in 
Trem2-deficient mice (Yuan et al., 2016). Earlier studies reported inconsistent results about 
the effect of TREM2 on amyloid plaque pathology (Jay et al., 2015, Ulrich et al., 2014, Wang 
et al., 2015), although it was later identified to be an age- and disease progression-dependent 
effect (Jay et al., 2017, Parhizkar et al., 2019). Moreover, Trem2 upregulation increases the 
phagocytic ability of plaque-surrounding microglia as indicated by plaque-derived material 
found in the DAM population (Keren-Shaul et al., 2017, Yuan et al., 2016, Parhizkar et al., 
2019).  
Recently, Zhong and colleagues reported a protective function of sTREM2 in Aβ-depositing 
mice (Zhong et al., 2019). They demonstrated that similarly to full-length Trem2, sTREM2 
reduced plaque deposition and associated dystrophic neurites by enhancing microglial 
proliferation, migration and clustering around plaques as well as lysosomal degradation of Aβ. 
Additionally, sTREM2 rescued long-term potentiation and memory deficits, which are 
otherwise impaired by Aβ plaque deposition in 5xFAD mice. All effects were attenuated 
following microglia depletion, suggesting that sTREM2 mediates its protective effects 
primarily through microglia and that microglia are central to modifying synaptic plasticity and 
amyloidogenesis. Thus, the CSF sTREM2 increase observed at the prodromal mild cognitive 
impairment stage of AD patients (Suarez-Calvet et al., 2016b) may represent a protective 
response to the initial threat caused by Aβ plaques that likely drive the pathogenic cascades of 
AD (Hardy and Higgins, 1992, Hardy and Selkoe, 2002). The functional similarities between 
sTrem2 and Trem2 may pose a challenge for therapeutic modulation of TREM2. This is 
because while blocking ADAM-mediated cleavage may enhance the protective functions of 
TREM2 due to increase signalling, reducing sTrem2 may present detrimental side effects that 
would be difficult to predict, especially since a receptor for sTrem2 has not yet been identified. 
4. ApoE – Structure and function 
ApoE is highly induced in DAM similarly to Trem2 (Keren-Shaul et al., 2017, Krasemann et 
al., 2017). Under healthy physiological conditions, the 299 amino acid glycoprotein is highly 
expressed in the liver, and in the brain, primarily by astrocytes (Zhang et al., 2014, Zhang et 
al., 2016), as well as microglia and damaged neurons to a lesser extent (Xu et al., 2006). ApoE 
is mainly known as a major cholesterol carrier in the brain that maintains the structure of 
specific lipoproteins (Kim et al., 2009a). Native ApoE is primarily lipidated by Adenosine 
triphosphate-binding cassette transporter A1 (ABCA1) in the brain. Additionally, ApoE 
facilitates transport of lipids among different cell types by serving as a ligand for the LDL 
receptor (LDLR) family and lipoprotein receptor-related protein (LRP) (Kim et al., 2009a) 
(Figure 1.7). 
Compared to humans that express three major isoforms of ApoE, with ApoE3 being the most 
predominant isoform, mice express only one type of ApoE protein (Kim et al., 2009a). The 
human ApoE include two separate N- and C-terminal domains joined by a flexible hinge. The 
N-terminus includes the receptor binding regions, which differs in the ApoE isoform residues 
(ApoE4, arginine 112; ApoE3 and ApoE2, cysteine 112). The C-terminal domain contains the 
lipid-binding region (residues 244-272) (Bu, 2009). The cysteine residue at 112 found in both 
ApoE2 and ApoE3 may form disulphide-linked dimers, whereas the arginine residue in ApoE4 
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significantly impedes lipid binding (Weisgraber, 1990, Weisgraber and Shinto, 1991). 
Additionally, while ApoE3 and ApoE4 that have arginine at residue 158 display normal 
receptor binding activity, ApoE2 with cysteine shows impaired receptor binding abilities and 
is associated with the recessive form of type III hyperlipoproteinemia (Ahn et al., 2009, 
Weisgraber et al., 1990, Weisgraber et al., 1994, Weisgraber and Shinto, 1991). This suggests 
that the differences in one or two amino acids in the N- and C-terminal domains significantly 
alter their interaction and preference to bind lipid and receptor proteins involved in cholesterol 
uptake (Mahley and Huang, 2012). To date, it is not clear how the function of ApoE as a lipid 
redistributor is mechanistically related to several diseases including AD, Down’s syndrome-
associated dementia and CAA. However, the ε4 allele disease risk association suggests that 
ApoE might contribute to these diseases by influencing synaptic plasticity, tau 
hyperphosphorylation, impairments in BBB integrity, neuroinflammation, as well as Aβ 
aggregation and clearance (Holtzman and Fagan, 1998, Kim et al., 2009a, Mahley and Huang, 
2012). 
4.1 ApoE and Aβ pathology  
ApoE was found to be a constituent of amyloid plaques (Corder et al., 1993, Strittmatter et al., 
1993b) with a positive correlation between copies of APOE ε4 alleles and senile plaque density 
(Rebeck et al., 1993, Schmechel et al., 1993). The APOE ε4 gene dosage has also been closely 
linked to fibrillar Aβ and low Aβ42 levels in CSF (Morris et al., 2010, Sunderland et al., 2004). 
Earlier studies on ApoE often produced inconsistent findings as it was later found that the 
affinity for ApoE to bind to Aβ highly depended on the lipidation state of ApoE, the Aβ species, 
as well as the pH levels of the in vitro model system (LaDu et al., 1994, Sanan et al., 1994, 
Strittmatter et al., 1993a). The isoform-dependent effects on Aβ aggregation was better 
understood using transgenic mice expressing human ApoE alleles crossed with APP transgenic 
models. For example, while Aβ burden was significantly reduced in ApoE-null PDAPP mice 
(Bales et al., 1999), mice lacking endogenous ApoE but expressing ε3 or ε4 isoform displayed 
less Aβ deposition compared to mice expressing endogenous ApoE. These findings suggest 
that human ApoE influences Aβ clearance (Holtzman et al., 2000). It is not yet known how 
exactly ApoE interacts with Aβ and influences its clearance, though several mechanisms have 
been proposed including, enzymatic degradation (Jiang et al., 2008), cellular uptake (Thal et 
al., 2000, Yeh et al., 2016, Ulrich et al., 2018), interaction with receptors and transporters on 
cell surface (Verghese et al., 2013), transport across the BBB (Cirrito et al., 2005), and ISF-
CSF flow (Castellano et al., 2011, Cirrito et al., 2003). ApoE4-expressing PDAPP mice display 
higher ISF Aβ levels with a slower Aβ clearance rate compared to ApoE3 mice. In comparison, 
ApoE2-expressing mice show lowest ISF Aβ and fastest Aβ clearance (Cirrito et al., 2003). 
Additionally, immunotherapy studies using anti-ApoE antibody in amyloid plaque-bearing 
mouse models have shown to reduce Aβ plaque burden in an antibody dose-dependent manner 
(Liao et al., 2014, Kim et al., 2012). Targeting ApoE with anti-sense oligonucleotides from 
birth also appeared to reduce Aβ plaque pathology; however, the effect was lost if the treatment 
started after onset of plaque formation (Huynh et al., 2017). 
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Figure 1.7 ApoE production, lipidation and its interaction with Aβ. Under stress or inflammation, 
ApoE is produced by astrocytes and DAM, and to a lesser extent in neurons. ApoE is lipidated in the 
astrocytes by ABCA1 and secreted into the interstitial fluid. The process begins once sufficient 
phospholipids and cholesterol bind to ABCA1, which triggers a conformational change leading to its 
dimerisation. The lipidated dimers immobilise actin filaments on the plasma membrane until lipid-free 
ApoE directly binds to the ABCA1 dimer. Upon binding, ApoE is lipidated by ABCA1 and leaves the 
dimer, which once again dissociates into a monomer to begin the process again. ApoE-containing 
lipoprotein particles are endocytosed into other cells via LDLR and LRP, the major metabolic receptors 
for ApoE. Amyloidogenic APP processing leads to Aβ production and release from neurons into the 
interstitial fluid (ISF). ApoE may bind to monomeric and smaller oligomeric soluble Aβ species and 
facilitate its aggregation into Aβ plaques in an isoform-dependent manner. However, ApoE could also 
bind to Aβ to facilitate its uptake and clearance through microglia in a TREM2-dependent manner or 
across the BBB. Accordingly, ApoE may bind to TREM2 to promote a DAM profile and enhance 
phagocytic uptake of Aβ. 
More recent studies suggest that ApoE interacts with Aβ to affect its fibrillogenesis (Liu et al., 
2017) in an isoform dependent manner (Castellano et al., 2011, Fitz et al., 2012). While ApoE 
is largely lipidated in the brain, altering the ApoE lipidation state has a profound impact on Aβ 
fibrillization and inflammation. For example, LDLR-deficient 5xFAD mice displayed 
increased thioflavine S-positive fibrillar plaque burden compared to 5xFAD controls, with 
reduced microgliosis and astrogliosis (Katsouri and Georgopoulos, 2011). Similar results have 
been reported in Tg2576 transgenic mice lacking LDLR expression (Cao et al., 2006). In 
support of these findings, overexpression of LDLR in APPPS1 mice reduced endogenous 
ApoE levels and inhibited Aβ deposition, as well as increased Aβ clearance (Kim et al., 2009b). 
Furthermore, the intronic microRNA-33 supresses ABCA1 expression through translational 
repression or by inducing mRNA decay (Koldamova et al., 2005, Rayner et al., 2010). Thus, 
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ablating microRNA-33 expression significantly increased ABCA1 levels and ApoE lipidation, 
which in turn reduced Aβ levels in the brain (Kim et al., 2015). Similarly, overexpression of 
ABCA1 has shown to increase ApoE lipidation with a corresponding decrease in Aβ deposition 
in PDAPP mice (Wahrle et al., 2008). Whereas ABCA1 deficiency reduces ApoE levels in the 
brain and consequently elevates Aβ deposition in APP23 mice (Koldamova et al., 2005). 
4.1.1 TREM2-APOE modulation of Aβ pathology 
The effects of APOE on immune activation have largely focused on astroglia due to their 
significant contribution to modulation of synaptic activity, inflammation and regulation of the 
BBB. As nascent ApoE is primarily lipidated by ABCA1, which is heavily expressed in 
astrocytes in mice (Zhang et al., 2014, Zhang et al., 2016), studies on loss of ApoE function in 
the brain parenchyma or the BBB were mainly focused on astroglia (Funato et al., 1998, Thal 
et al., 2000, Koistinaho et al., 2004). Earlier studies indicated that ApoE affects receptor-
mediated phagocytosis by microglia (Paresce et al., 1997, Paresce et al., 1996, Uchihara et al., 
1995). However, most of these studies were performed in vitro, which may have heavily 
influenced the microglial signature, and therefore function (Butovsky and Weiner, 2018). Until 
recently, not much was known about the impact of loss of ApoE function on microgliosis. 
Interestingly, similar to Trem2 knockout mice (Wang et al., 2016, Yuan et al., 2016), ApoE-
deficient APPPS1-21 or APP/PS1de9 displayed impaired microglial clustering around Aβ 
plaques, which appeared enlarged with star-shaped fibrils (Ulrich et al., 2018). Furthermore, 
ApoE isoforms appear to have differential effects on microglial clustering around plaques, with 
ApoE4 displaying increased number of microglia around plaques compared to ApoE3 in mice 
(Rodriguez et al., 2014) but not in AD patients (Serrano-Pozo et al., 2013). Additionally, loss 
of Trem2 function mice display reduced ApoE/Aβ colocalisation with significantly decreased 
microglial ApoE compared to astroglial ApoE levels (Parhizkar et al., 2019). With recent 
developments in transcriptomic analysis, we now know that microglia also express genes 
required for ApoE production or lipidation, such as ABCA1 (Zhang et al., 2014, Zhang et al., 
2016). This suggests that along with ApoE secreted by astroglia, ApoE of microglial origin 
may have a profound effect on its phagocytic ability to modulate plaque pathology by 
influencing its aggregation and/or clearance. Thus, TREM2 and APOE may share similar 
mechanisms involving LOAD pathogenesis as a result of changes in microglial pathology 
(Krasemann et al., 2017). For example, TREM2 may bind to ApoE accumulated on the surfaces 
of damaged or dead neurons, which may enhance opsonisation and promote neuronal 
phagocytosis by microglia. However, the exact mechanism through which the interaction 
occurs, or whether they are upstream or downstream of each other remains to be determined in 
vivo.  
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II. Aim of the study 
Microglia are considered one of the key players in maintaining brain homeostasis through 
phagocytic removal of harmful pathogens such as Aβ plaques. In fact, microgliosis is one of 
the key pathological hallmarks of AD and other neurodegenerative diseases, as loss of 
microglial function is believed to be crucial in determining the outcome and progression of 
LOAD. This is supported by the recent GWAS reporting that more than half of AD risk genes 
are implicated in microglial and innate immune cell function, including the two top risk genes 
APOE and TREM2. The APOE ε4 allele is long known to be the strongest genetic risk factor 
for AD due to its pro-aggregating effects on Aβ as well as impaired plaque clearance. Both 
APOE and TREM2 mRNA expression are upregulated in microglia clustering around plaques 
and TREM2 deficiency is consistently reported to reduce the number of microglia around 
plaques. However, the functional role of TREM2 in amyloid metabolism remains controversial 
due to conflicting results from different transgenic model systems studied at different stages of 
Aβ pathology. Furthermore, it remains unclear whether these results from mouse models 
translate to human AD pathology. As Aβ accumulation and deposition in the brain likely drives 
the pathogenic cascade of AD, the major goal of my PhD thesis was to provide a critical link 
between Aβ metabolism and TREM2-dependent microglial response in the pathogenesis of 
AD. 
Do disease-associated TREM2 variants confer a loss-of-function? How does the FTD-
associated p.T66M variant impact microglial function in vivo? 
When I started my PhD, all functional studies on TREM2 were published using Trem2 
knockout mice, however very little was reported on the functional effects of disease-associated 
TREM2 variants. Therefore, I collaborated with Gernot Kleinberger and colleagues to 
characterise a mouse model expressing the FTD-like syndrome-associated Trem2 p.T66M 
mutation at an endogenous level. This variant has not been linked to AD, such as the p.R47H 
variant. However, in comparison, the p.T66M mutation displays stronger TREM2 loss-of-
function effects on TREM2 maturation, shedding and phagocytic uptake in vitro. Thus, to 
understand its functional consequences on microglia in vivo, I collected brain, cerebrospinal 
fluid and serum samples from WT, heterozygous and homozygous p.T66M-expressing mice 
of different ages. 
What is the factor connecting amyloidogenesis and microglial phagocytosis? How does 
the TREM2-Aβ interaction fit in the amyloid cascade hypothesis? 
To investigate a potential interaction between TREM2 and Aβ pathology, I used the amyloid 
seeding paradigm and analysed Trem2-dependent effects on early Aβ plaque formation as well 
as associated microgliosis in APPPS1 mice. For this, I included both APPPS1/Trem2-/- and 
APPPS1/Trem2p.T66M mice as loss of Trem2 function models. I extended the analyses to study 
changes in amyloidogenesis and microglial activity with aging in APPPS1 mice, which were 
not exogenously seeded. Lastly, I examined whether loss of Trem2 immunomodulatory 
functions can be linked to Aβ metabolism through changes in APOE and whether these 
pathological events can be confirmed in AD patients with TREM2 variants.   
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